文献速递神经儿科影像MR

钆匹醇与钆特酸葡甲胺用于儿童脑MRI的对比增强个体内比较

Gadopiclenol Versus Gadoterate Meglumine for Pediatric Brain MRI: An Intraindividual Comparison of Contrast Enhancement.
PubMed 文献 · AJR Am J Roentgenol · 2025-06-25

本回顾性研究纳入38例儿童患者,个体内比较钆匹醇(0.05 mmol/kg)与钆特酸葡甲胺(0.1 mmol/kg)脑MRI增强效果;钆匹醇在3D T1W FSE上脉络丛和3D T1W GRE上鼻甲的对比率更高,CNR无显著差异,读者对部分结构增强的偏好不一;结论支持儿童脑MRI使用半剂量钆匹醇。

要点

  • 钆匹醇0.05 mmol/kg在3D T1W FSE上脉络丛对比率高于钆特酸葡甲胺0.1 mmol/kg。
  • 两药所有结构-序列组合的CNR均无显著差异(p > .05)。
  • 读者对FLAIR上鼻甲增强更偏好钆特酸葡甲胺,其余组合多无显著偏好。

核心结论

  • 研究结果支持儿童脑MRI检查使用半标准剂量的钆匹醇。

研究设计与样本

  • 回顾性个体内比较研究,纳入38例儿童患者(平均年龄11.1岁;男25例,女13例),比较钆匹醇0.05 mmol/kg与钆特酸葡甲胺0.1 mmol/kg增强脑MRI,使用相同场强和协议,分别分析3D T1W FSE(27例)、3D T1W GRE(11例)和2D FLAIR(22例)增强序列。

关键影像表现/征象

  • 3D T1W FSE上脉络丛对比率钆匹醇71.0 ± 17.8 vs 钆特酸葡甲胺63.4 ± 37.2(p = .04)。
  • 3D T1W GRE上鼻甲对比率钆匹醇81.7 ± 21.8 vs 钆特酸葡甲胺58.1 ± 25.2(p = .01)。
  • 其余结构-序列组合的对比率两药间无显著差异(p > .05)。
  • 所有结构-序列组合的CNR两药间均无显著差异(p > .05)。

诊断标准与关键数值

  • 对比率(CR)和对比噪声比(CNR)在生理强化结构(脉络丛、垂体、硬脑膜静脉窦、鼻甲黏膜)上测量。
  • 两名神经放射科医生采用Likert量表(-2至2)盲法并排比较,确定对生理强化结构(脉络丛、垂体、硬脑膜静脉窦、鼻甲黏膜、硬脑膜)增强特征化的偏好序列。
  • 读者1和读者2均偏好钆匹醇在3D T1W FSE上显示脉络丛(读者1:-0.4 ± 0.5,p = .005;读者2:-0.5 ± 0.8,p = .02)和垂体(读者1:-0.5 ± 0.7,p < .001;读者2:-0.5 ± 0.9,p = .009)。
  • 读者2还偏好钆匹醇在3D T1W FSE上显示鼻甲(-0.7 ± 0.7,p < .001)。
  • 读者1和读者2均偏好钆特酸葡甲胺在FLAIR上显示鼻甲(读者1:0.3 ± 0.5,p = .01;读者2:0.5 ± 0.8,p = .02);读者2还偏好钆特酸葡甲胺在FLAIR上显示脉络丛(0.5 ± 0.8,p = .01)。

临床应用与阅片要点

  • 儿童脑MRI增强可考虑使用钆匹醇0.05 mmol/kg,但原文未给出具体推荐等级。
  • 在3D T1W FSE序列上,钆匹醇对脉络丛和垂体的增强显示可能更受读者偏好。
  • 在FLAIR序列上,钆特酸葡甲胺对鼻甲和脉络丛的增强显示可能更受读者偏好。
  • 使用钆匹醇可能有助于减少需要系列MRI检查儿童的累积钆暴露。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The macrocyclic agent gadopiclenol, FDA-approved in 2022, has relatively high T1 relaxivity, allowing substantial dose reductions. OBJECTIVE. The purpose of this study was to perform an intraindividual quantitative and qualitative comparison of contrast enhancement between brain MRI examinations in pediatric patients performed using gadopiclenol (0.05 mmol/kg) and gadoterate meglumine (0.1 mmol/kg). METHODS. This retrospective study included 38 pediatric patients (mean age: 11.1 years; 25 male patients, 13 female patients) who underwent gadopiclenol-enhanced brain MRI (0.05 mmol/kg) from December 1, 2024, to March 31, 2025, and gadoterate meglumine-enhanced MRI (0.1 mmol/kg) within the prior 6 months using the same field strength and protocol. Data were separately analyzed for 3D T1-weighted (T1W) fast spin-echo (FSE), 3D T1W gradient-recalled echo (GRE), and 2D FLAIR postcontrast sequences (27, 11, and 22 patients, respectively). The contrast ratio (CR) and CNR were measured in physiologic enhancing structures (choroid plexus, pituitary, dural venous sinuses, turbinate mucosa). Two neuroradiologists identified a preferred sequence for characterizing enhancement of physiologic enhancing structures (choroid plexus, pituitary, dural venous sinuses, turbinate mucosa, dura mater) in side-by-side blinded comparisons using a Likert scale (-2 to 2). RESULTS. CR was higher for gadopiclenol than for gadoterate for the choroid plexus on 3D T1W FSE images (71.0 ± 17.8 vs 63.4 ± 37.2, p = .04) and turbinate on 3D T1W GRE images (81.7 ± 21.8 vs 58.1 ± 25.2, p = .01). The remaining comparisons of CR between the two agents were not significant (p > .05). The CNR was not significantly different between the two agents for any combination of structure and sequence (p > .05). Both readers, reader 1 (R1) and reader 2 (R2), preferred gadopiclenol on 3D T1W FSE images for the choroid plexus (R1 [mean score ± SD]: -0.4 ± 0.5, p = .005; R2: -0.5 ± 0.8, p = .02) and pituitary (R1: -0.5 ± 0.7, p < .001; R2: -0.5 ± 0.9, p = .009). R2 also preferred gadopiclenol on 3D T1W FSE images for the turbinate (mean score ± SD, -0.7 ± 0.7; p < .001). Both readers preferred gadoterate meglumine on FLAIR images for the turbinate (R1: 0.3 ± 0.5, p = .01; R2: 0.5 ± 0.8, p = .02). R2 also preferred gadoterate meglumine on FLAIR images for the choroid plexus (mean score ± SD, 0.5 ± 0.8; p = .01). Neither reader had a significant preference for either agent for the remaining combinations of structure and sequence (p > .05). CONCLUSION. The findings support use of gadopiclenol at half the standard gadolinium dose for pediatric brain MRI examinations. CLINICAL IMPACT. The use of gadopiclenol could facilitate reductions in cumulative gadolinium exposure in children requiring serial MRI examinations.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Valencia S, Cortes-Albornoz MC, Ferracioli SF, et al. Gadopiclenol Versus Gadoterate Meglumine for Pediatric Brain MRI: An Intraindividual Comparison of Contrast Enhancement. AJR Am J Roentgenol. 2025. PMID: 40557986. doi:10.2214/AJR.25.33201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。